In this line, DPP4i vildagliptin reduces hippocampal Aß42 levels and preserves neuronal integrity in AD-PreDM mice [225], while also decreasing APP expression and tau hyperphosphorylation in an AD-T2D rat model [228]. Here, MAPT is linked to Alzheimer disease.